CASI Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Asset-based net asset value (liquidation) analysis: total assets approx $21.0M, total liabilities $79.3M, shareholders' deficit $58.3M (H1 2026 10-Q/6-K), i.e. -$2.84/share across 20.56M shares outstanding; floored at $0.00 under limited liability. Cross-checked with TTM figures: cash $3.77M, total debt $40.50M (net debt -$36.73M), TTM revenue $20.1M, TTM FCF -$20.8M, current ratio 0.15, Altman Z-score -59.2.

Reasoning: CASI Pharmaceuticals is a commercial-stage specialty pharma with negative shareholders' equity, negative free cash flow, a 0.15 current ratio, and going-concern risk; a standard growth DCF is not meaningful when FCF is structurally negative, so a liquidation/NAV floor is the more defensible intrinsic estimate.